---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-000959"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:10:39.978208+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical Q3 FY2026: cash $7.0M; operating loss $2.06M up 13.6% YoY

## Summary
- Cash balance of ~$7.0M as of Dec 31, 2025; no revenue reported.
- Q3 operating loss of $2.06M vs $1.81M in prior year, driven by higher payroll costs.
- Nine-month operating expenses down 26.9% to $5.36M from $7.34M YoY.
- Cohort 2 of Australian oncology trial progressing; Hemopurifier compatibility study with SLAMB system underway.
- Preclinical Long COVID data published on bioRxiv; submitted for peer review.

## SEC filing metadata
- accession: 0001683168-26-000959
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316826000959/0001683168-26-000959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316826000959/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-000959
- JSON: https://secwatch.observer/filing/0001683168-26-000959.json
- Plain text: https://secwatch.observer/filing/0001683168-26-000959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.